1. DURABILITY OF COMPLETE RESPONSE AFTER BLINATUMOMAB THERAPY FOR REFRACTORY/RELAPSED AGGRESSIVE B‐CELL NON‐HODGKIN LYMPHOMA. (12th June 2019) Authors: Viardot, A.; Hess, G.; Bargou, R.; Morley, N.J.; Gritti, G.; Iskander, K.; Cohan, D.; Zhang, A.; Franklin, J.; Coyle, L. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 429 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LONG‐TERM OUTCOME OF PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐ HODGKIN LYMPHOMA TREATED WITH BISPECIFIC ANTIBODY BLINATUMOMAB IN A PHASE I TRIAL. (12th June 2019) Authors: Dufner, V.; Sayheli, C.; Gelbrich, G.; Bargou, R.; Goebeler, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 325 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗